Dataset from A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study to Compare the Efficacy of Inhaled Tiotropium + Olodaterol, Fixed Dose Combination (5 mcg/5mcg) vs. Placebo Delivered by Respimat Inhaler in Patients With Moderate to Severe COPD, Stratified by Peak Inspiratory Flow Rate [TRONARTO].

To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function
in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal
and sub-optimal Peak Inspiratory Flow Rate (PIFR). Disease severity (moderate to severe) is
based on the Global Initiative for Chronic Lung Disease (GOLD) guidelines (GOLD 2 - 3)